ERBB2 and non-small cell lung carcinoma: In 2015, De Grève et al. assessed the efficacy of the quinazoline-based, irreversible pan-HER TKI afatinib in pretreated patients with advanced or metastatic NSCLC harboring HER2 exon 20 mutations (Table 1) [54].